Cancer Vaccines Market Report and Forecast 2025-2034
Description
The global cancer vaccines market size was valued at USD 8.00 Billion in 2024, driven by the increasing initiatives by pharma giants to develop the most effective cancer vaccine. The market size is anticipated to grow at a CAGR of 11.80% during the forecast period of 2025-2034 to achieve a value of USD 24.41 Billion by 2034.
Global Cancer Vaccines Market Overview
The market is propelled by the researchers putting their maximum efforts into discovering innovative combinations and developing effective cancer vaccines for several types of cancers. The cancer vaccines market demand is driven by the increasing prevalence of cancer cases globally. In 2023, around 20 million new cases of cancer were diagnosed and nearly 10 million deaths were reported across the world. The cancer burden is poised to increase by approximately 60% over the next two decades, further straining health systems, people, and communities. The predicted global burden will increase to about 30 million new cancer cases by 2040, with high incidence in low- and middle-income countries. As a result, industry leaders are coming together to collaborate, perform clinical trials, and develop cancer vaccine candidates.
Rising Adoption of Innovative Alternatives to Offer Precise Treatment
In August 2023, the National Health Service (NHS) England, United Kingdom’s publicly funded healthcare system rolled out an anti-cancer jab that can cut down treatment time for some by three-quarters. Atezolizumab (Tencentriq®), an immunotherapy drug has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and takes around 7 minutes to administer intravenously, which is significantly lesser than the conventional time span.
The release of this injection is a piece of good news for both the patients and healthcare providers as it facilitates oncologists to provide faster treatment to patients and deliver it conveniently. This approach will likely contribute to increased awareness among patients and offer notable cancer vaccines market growth in the forecast period. The rapid adaptation of innovation by the NHS indicates the commitment to improve the efficiency of health services.
Strategic Collaborations between Market Players
In October 2023, BioNTech SE revealed that Autogene cevumeran (also known as BNT122, RO7198457), a therapeutic individualized cancer vaccine candidate for pancreatic ductal adenocarcinoma (PDAC) treatment was moved to Phase 2 trials after showing promising results in the Phase 1 clinical trials. In the Phase 2 trial, the efficacy is expected to be evaluated in 260 patients, in combination with anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy. The combination treatment will be tested against the current standard-of-care chemotherapy (mFOLFIRINOX).
The candidate is being jointly developed by BioNTech and Genentech (a member of the Roche Group) and is based on mRNA-based individualized neoantigen-specific immunotherapy (iNeST) platform. The alliance of prominent companies to devise improved and personalized solutions is a major market trend poised to impact the cancer vaccines market share positively in the forecast period.
Global Cancer Vaccines Market Segmentation
Cancer Vaccines Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Technology
Geographically, North America is expected to dominate the market during the forecast period. In 2023, the region reported 609,280 cancer related deaths. According to the National Cancer Institute, an estimated 2 million people are expected to be diagnosed with cancer in the United States in 2024. By 2040, the number of people expected to be diagnosed with cancer will increase by 57%, and approximately affect 6.23 million people. As a result, there has been significant emphasis on developing effective solutions for the prevention of cancer associated mortalities.
Europe holds a notable cancer vaccines market share, owing to the presence of prominent academic and research institutions along with an extensive budget to promote research activities. The increasing collaborations between healthcare companies and academic institutions is expected to drive significant market growth in the region. The Asia-Pacific region is witnessing growth, which can be attributed to rising integration of modern technologies into the medical ecosystem. The increasing efforts by the governments of emerging economies to improve the infrastructure is another notable market trend in the region.
Global Cancer Vaccines Market: Competitor Landscape
In February 2023, Moderna, Inc. and Merck announced that the FDA granted a breakthrough therapy designation to mRNA-4157/V940 in combination with pembrolizumab (Keytruda) for the adjuvant treatment of patients with high-risk melanoma following complete resection. The grant was based on the positive results from the phase 2b KEYNOTE-942 trial (NCT03897881). mRNA-4157/V940 is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine made of a single synthetic mRNA coding for up to 34 neoantigens. It works by instigating a natural immune response and generating specific T cell responses.
The key features of the cancer vaccines market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Global Cancer Vaccines Market Overview
The market is propelled by the researchers putting their maximum efforts into discovering innovative combinations and developing effective cancer vaccines for several types of cancers. The cancer vaccines market demand is driven by the increasing prevalence of cancer cases globally. In 2023, around 20 million new cases of cancer were diagnosed and nearly 10 million deaths were reported across the world. The cancer burden is poised to increase by approximately 60% over the next two decades, further straining health systems, people, and communities. The predicted global burden will increase to about 30 million new cancer cases by 2040, with high incidence in low- and middle-income countries. As a result, industry leaders are coming together to collaborate, perform clinical trials, and develop cancer vaccine candidates.
Rising Adoption of Innovative Alternatives to Offer Precise Treatment
In August 2023, the National Health Service (NHS) England, United Kingdom’s publicly funded healthcare system rolled out an anti-cancer jab that can cut down treatment time for some by three-quarters. Atezolizumab (Tencentriq®), an immunotherapy drug has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and takes around 7 minutes to administer intravenously, which is significantly lesser than the conventional time span.
The release of this injection is a piece of good news for both the patients and healthcare providers as it facilitates oncologists to provide faster treatment to patients and deliver it conveniently. This approach will likely contribute to increased awareness among patients and offer notable cancer vaccines market growth in the forecast period. The rapid adaptation of innovation by the NHS indicates the commitment to improve the efficiency of health services.
Strategic Collaborations between Market Players
In October 2023, BioNTech SE revealed that Autogene cevumeran (also known as BNT122, RO7198457), a therapeutic individualized cancer vaccine candidate for pancreatic ductal adenocarcinoma (PDAC) treatment was moved to Phase 2 trials after showing promising results in the Phase 1 clinical trials. In the Phase 2 trial, the efficacy is expected to be evaluated in 260 patients, in combination with anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy. The combination treatment will be tested against the current standard-of-care chemotherapy (mFOLFIRINOX).
The candidate is being jointly developed by BioNTech and Genentech (a member of the Roche Group) and is based on mRNA-based individualized neoantigen-specific immunotherapy (iNeST) platform. The alliance of prominent companies to devise improved and personalized solutions is a major market trend poised to impact the cancer vaccines market share positively in the forecast period.
Global Cancer Vaccines Market Segmentation
Cancer Vaccines Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Technology
- Recombinant Cancer Vaccines
- Whole-Cell Cancer Vaccines
- Viral Vector and DNA Cancer Vaccines
- Other Technologies
- Preventive Vaccine
- Therapeutic Vaccine
- Prostate Cancer
- Cervical Cancer
- Melanoma
- Bladder Cancer
- Other Applications
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Geographically, North America is expected to dominate the market during the forecast period. In 2023, the region reported 609,280 cancer related deaths. According to the National Cancer Institute, an estimated 2 million people are expected to be diagnosed with cancer in the United States in 2024. By 2040, the number of people expected to be diagnosed with cancer will increase by 57%, and approximately affect 6.23 million people. As a result, there has been significant emphasis on developing effective solutions for the prevention of cancer associated mortalities.
Europe holds a notable cancer vaccines market share, owing to the presence of prominent academic and research institutions along with an extensive budget to promote research activities. The increasing collaborations between healthcare companies and academic institutions is expected to drive significant market growth in the region. The Asia-Pacific region is witnessing growth, which can be attributed to rising integration of modern technologies into the medical ecosystem. The increasing efforts by the governments of emerging economies to improve the infrastructure is another notable market trend in the region.
Global Cancer Vaccines Market: Competitor Landscape
In February 2023, Moderna, Inc. and Merck announced that the FDA granted a breakthrough therapy designation to mRNA-4157/V940 in combination with pembrolizumab (Keytruda) for the adjuvant treatment of patients with high-risk melanoma following complete resection. The grant was based on the positive results from the phase 2b KEYNOTE-942 trial (NCT03897881). mRNA-4157/V940 is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine made of a single synthetic mRNA coding for up to 34 neoantigens. It works by instigating a natural immune response and generating specific T cell responses.
The key features of the cancer vaccines market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Dendreon Pharmaceuticals LLC
- Bristol Myers Squibb Company
- AstraZeneca
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Sanofi
- Pfizer Inc.
- Gilead Sciences, Inc.
- Inovio Pharmaceuticals
- Bavarian Nordic
- CureVac SE
- Takeda Pharmaceutical Company Limited
- Cascadian Therapeutics
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Cancer Vaccines Market Overview
- 3.1 Global Cancer Vaccines Market Historical Value (2018-2024)
- 3.2 Global Cancer Vaccines Market Forecast Value (2025-2034)
- 4 Global Cancer Vaccines Market Landscape*
- 4.1 Global Cancer Vaccines: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Cancer Vaccines: Product Landscape
- 4.2.1 Analysis by Products
- 4.2.2 Analysis by Application
- 5 Global Cancer Vaccines Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Cancer Vaccines Market Segmentation (218-2034)
- 6.1 Global Cancer Vaccines Market by Technology
- 6.1.1 Market Overview
- 6.1.2 Recombinant Cancer Vaccines
- 6.1.3 Whole-Cell Cancer Vaccines
- 6.1.4 Viral Vector and DNA Cancer Vaccines
- 6.1.5 Other Technologies
- 6.2 Global Cancer Vaccines Market by Vaccine Type
- 6.2.1 Market Overview
- 6.2.2 Preventive Vaccine
- 6.2.3 Therapeutic Vaccine
- 6.3 Global Cancer Vaccines Market by Application
- 6.3.1 Market Overview
- 6.3.2 Prostate Cancer
- 6.3.3 Cervical Cancer
- 6.3.4 Melanoma Bladder Cancer
- 6.3.5 Other Applications
- 6.4 Global Cancer Vaccines Market by Region
- 6.4.1 Market Overview
- 6.4.2 North America
- 6.4.3 Europe
- 6.4.4 Asia Pacific
- 6.4.5 Latin America
- 6.4.6 Middle East and Africa
- 7 North America Cancer Vaccines Market (218-2034)
- 7.1 North America Cancer Vaccines Market (2018-2034) by Technology
- 7.1.1 Market Overview
- 7.1.2 Recombinant Cancer Vaccines
- 7.1.3 Whole-Cell Cancer Vaccines
- 7.1.4 Viral Vector and DNA Cancer Vaccines
- 7.1.5 Other Technologies
- 7.2 North America Cancer Vaccines Market (2018-2034) by Vaccine Type
- 7.2.1 Market Overview
- 7.2.2 Preventive Vaccine
- 7.2.3 Therapeutic Vaccine
- 7.3 North America Cancer Vaccines Market (2018-2034) by Country
- 7.3.1 United States of America
- 7.3.2 Canada
- 8 Europe Vaccines Market (218-2034)
- 8.1 Europe Cancer Vaccines Market (2018-2034) by Technology
- 8.1.1 Market Overview
- 8.1.2 Recombinant Cancer Vaccines
- 8.1.3 Whole-Cell Cancer Vaccines
- 8.1.4 Viral Vector and DNA Cancer Vaccines
- 8.1.5 Other Technologies
- 8.2 Europe Cancer Vaccines Market (2018-2034) by Vaccine Type
- 8.2.1 Market Overview
- 8.2.2 Preventive Vaccine
- 8.2.3 Therapeutic Vaccine
- 8.3 Europe Cancer Vaccines Market (2018-2034) by Country
- 8.3.1 United Kingdom
- 8.3.2 Germany
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Others
- 9 Asia Pacific Cancer Vaccines Market (218-2034)
- 9.1 Asia Pacific Cancer Vaccines Market (2018-2034) by Technology
- 9.1.1 Market Overview
- 9.1.2 Recombinant Cancer Vaccines
- 9.1.3 Whole-Cell Cancer Vaccines
- 9.1.4 Viral Vector and DNA Cancer Vaccines
- 9.1.5 Other Technologies
- 9.2 Asia Pacific Cancer Vaccines Market (2018-2034) by Vaccine Type
- 9.2.1 Market Overview
- 9.2.2 Preventive Vaccine
- 9.2.3 Therapeutic Vaccine
- 9.3 Asia Pacific Cancer Vaccines Market (2018-2034) by Country
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 ASEAN
- 9.3.5 Australia
- 9.3.6 Others
- 10 Latin America Cancer Vaccines Market (218-2034)
- 10.1 Latin America Cancer Vaccines Market (2018-2034) by Technology
- 10.1.1 Market Overview
- 10.1.2 Recombinant Cancer Vaccines
- 10.1.3 Whole-Cell Cancer Vaccines
- 10.1.4 Viral Vector and DNA Cancer Vaccines
- 10.1.5 Other Technologies
- 10.2 Latin America Cancer Vaccines Market (2018-2034) by Vaccine Type
- 10.2.1 Market Overview
- 10.2.2 Preventive Vaccine
- 10.2.3 Therapeutic Vaccine
- 10.3 Latin America Cancer Vaccines Market (2018-2034) by Country
- 10.3.1 Brazil
- 10.3.2 Argentina
- 10.3.3 Mexico
- 10.3.4 Others
- 11 Middle East and Africa Cancer Vaccines Market (218-2034)
- 11.1 Middle East and Africa Cancer Vaccines Market (2018-2034) by Technology
- 11.1.1 Market Overview
- 11.1.2 Recombinant Cancer Vaccines
- 11.1.3 Whole-Cell Cancer Vaccines
- 11.1.4 Viral Vector and DNA Cancer Vaccines
- 11.1.5 Other Technologies
- 11.2 Middle East and Africa Cancer Vaccines Market (2018-2034) by Vaccine Type
- 11.2.1 Market Overview
- 11.2.2 Preventive Vaccine
- 11.2.3 Therapeutic Vaccine
- 11.3 Middle East and Africa Cancer Vaccines Market (2018-2034) by Country
- 11.3.1 Saudi Arabia
- 11.3.2 United Arab Emirates
- 11.3.3 Nigeria
- 11.3.4 South Africa
- 11.3.5 Others
- 12 Regulatory Framework
- 12.1 Regulatory Overview
- 12.1.1 US FDA
- 12.1.2 EU EMA
- 12.1.3 INDIA CDSCO
- 12.1.4 JAPAN PMDA
- 12.1.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication Year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
- 14.1 Analysis by Year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by NIH Departments
- 14.7 Analysis by Recipient Organization
- 15 Clinical Trials Analysis
- 15.1 Analysis by Trial Registration Year
- 15.2 Analysis by Trial Status
- 15.3 Analysis by Trial Phase
- 15.4 Analysis by Therapeutic Area
- 15.5 Analysis by Geography
- 16 Funding and Investment Analysis
- 16.1 Analysis by Funding Instances
- 16.2 Analysis by Type of Funding
- 16.3 Analysis by Funding Amount
- 16.4 Analysis by Leading Players
- 16.5 Analysis by Leading Investors
- 16.6 Analysis by Geography
- 17 Partnership and Collaborations Analysis
- 17.1 Analysis by Partnership Instances
- 17.2 Analysis by Type of Partnership
- 17.3 Analysis by Leading Players
- 17.4 Analysis by Geography
- 18 Supplier Landscape
- 18.1 Merck & Co., Inc.
- 18.1.1 Financial Analysis
- 18.1.2 Product Portfolio
- 18.1.3 Demographic Reach and Achievements
- 18.1.4 Mergers and Acquisitions
- 18.1.5 Certifications
- 18.2 GlaxoSmithKline plc.
- 18.2.1 Financial Analysis
- 18.2.2 Product Portfolio
- 18.2.3 Demographic Reach and Achievements
- 18.2.4 Mergers and Acquisitions
- 18.2.5 Certifications
- 18.3 Dendreon Pharmaceuticals LLC
- 18.3.1 Financial Analysis
- 18.3.2 Product Portfolio
- 18.3.3 Demographic Reach and Achievements
- 18.3.4 Mergers and Acquisitions
- 18.3.5 Certifications
- 18.4 Bristol Myers Squibb Company
- 18.4.1 Financial Analysis
- 18.4.2 Product Portfolio
- 18.4.3 Demographic Reach and Achievements
- 18.4.4 Mergers and Acquisitions
- 18.4.5 Certifications
- 18.5 AstraZeneca
- 18.5.1 Financial Analysis
- 18.5.2 Product Portfolio
- 18.5.3 Demographic Reach and Achievements
- 18.5.4 Mergers and Acquisitions
- 18.5.5 Certifications
- 18.6 F. Hoffmann-La Roche Ltd.
- 18.6.1 Financial Analysis
- 18.6.2 Product Portfolio
- 18.6.3 Demographic Reach and Achievements
- 18.6.4 Mergers and Acquisitions
- 18.6.5 Certifications
- 18.7 Novartis AG
- 18.7.1 Financial Analysis
- 18.7.2 Product Portfolio
- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Mergers and Acquisitions
- 18.7.5 Certifications
- 18.8 Sanofi
- 18.8.1 Financial Analysis
- 18.8.2 Product Portfolio
- 18.8.3 Demographic Reach and Achievements
- 18.8.4 Mergers and Acquisitions
- 18.8.5 Certifications
- 18.9 Pfizer Inc.
- 18.9.1 Financial Analysis
- 18.9.2 Product Portfolio
- 18.9.3 Demographic Reach and Achievements
- 18.9.4 Mergers and Acquisitions
- 18.9.5 Certifications
- 18.10 Gilead Sciences, Inc.
- 18.10.1 Financial Analysis
- 18.10.2 Product Portfolio
- 18.10.3 Demographic Reach and Achievements
- 18.10.4 Mergers and Acquisitions
- 18.10.5 Certifications
- 18.11 Inovio Pharmaceuticals
- 18.11.1 Financial Analysis
- 18.11.2 Product Portfolio
- 18.11.3 Demographic Reach and Achievements
- 18.11.4 Mergers and Acquisitions
- 18.11.5 Certifications
- 18.12 Bavarian Nordic
- 18.12.1 Financial Analysis
- 18.12.2 Product Portfolio
- 18.12.3 Demographic Reach and Achievements
- 18.12.4 Mergers and Acquisitions
- 18.12.5 Certifications
- 18.13 CureVac SE
- 18.13.1 Financial Analysis
- 18.13.2 Product Portfolio
- 18.13.3 Demographic Reach and Achievements
- 18.13.4 Mergers and Acquisitions
- 18.13.5 Certifications
- 18.14 Takeda Pharmaceutical Company Limited
- 18.14.1 Financial Analysis
- 18.14.2 Product Portfolio
- 18.14.3 Demographic Reach and Achievements
- 18.14.4 Mergers and Acquisitions
- 18.14.5 Certifications
- 18.15 Cascadian Therapeutics
- 18.15.1 Financial Analysis
- 18.15.2 Product Portfolio
- 18.15.3 Demographic Reach and Achievements
- 18.15.4 Mergers and Acquisitions
- 18.15.5 Certifications
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
